Neuroprotective Pre-clinical Efficacy Testing of New Drug Candidates

Opportunity

High-Throughput Analysis of Pre-Clinical Drug Candidates associated with Neurodegenerative Diseases

Inventors

Ronald Tjalkens
Kenneth Olson
Collin Bantle

At A Glance

​Researchers at Colorado State University have developed a high-throughput screening for both Research and Pharma/Biotech companies interested in examining the efficacy or safety of new leads in brain tissue for pre-clinical studies.

The high-throughput method includes use of a proprietary method of modeling neurodegeneration that enables features of neurological disease such as neuronal loss and protein aggregation to be achieved in days rather than months.  Together, the screening method dramatically decreases the time required for efficacy testing of new chemical or biological drug candidates.

For more details, please contact our office.

Licensing Director

Steve Foster
Steve.Foster@colostate.edu
970-491-7100

Reference No.:  19-005

Background

​Current models for neurodegenerative diseases such as Parkinson’s and Alzheimer’s, particularly those for inducing protein aggregation, can take 1 – 2 years to induce symptoms, often without the full spectrum of features seen in the human clinical disorders. Our method of virally-induced neurodegeneration coupled to high-throughput analysis enables features of neurological disease such as neuronal loss and protein aggregation to be achieved in days rather than months, dramatically decreasing the time required for efficacy testing of new chemical or biological drug candidates. Critically, protein aggregation as seen in Parkinson’s and Alzheimer’s diseases can be induced and analyzed within weeks, rather than the current state of the art, which takes typically from 1 – 2 years.

Technology Overview

Researchers at Colorado State University have developed a method for high-throughput analysis of brain tissue for the purpose of determining neural cell counts and for neuroprotective efficacy testing in research or clinical samples. This method was developed in order to increase the efficiency and reduce the time required in determining whether pharmacological or genetic manipulations of research animals were effective in mitigating disease outcomes in models of neurodegeneration for Parkinson’s disease, Alzheimer’s disease and neurotoxic brain injury.

The high-throughput method uses robotic tissue staining for histological preparation of multiple samples, coupled with automated imaging and computer-assisted counting algorithms to determine cell numbers and phenotype. When coupled to disease models (such as our proprietary method of modeling neurodegeneration) this method enables features of neurological disease such as neuronal loss and protein aggregation to be achieved in days rather than months, dramatically decreasing the time required for efficacy testing of new chemical or biological drug candidates.

Benefits
  • Method for modeling neurodegeneration is achieved in days
  • Significantly decreased time required for efficacy testing of new drug candidates
  • Uses robotic tissue staining for histological preparation of multiple samples
Applications
  • Pre-clinical neuroprotective efficacy testing of new drug candidates
  • Applicable of neurodegenerative diseases

Last updated: October 2020

Add keywords or various names of inventors here (text is hidden)